Global HER-2 Positive Breast Cancer Market 2015-2019

About HER-2 Positive Breast Cancer
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA  
     
Key Vendors
• Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi

Other Prominent Vendors
 • Actavis
• Array BioPharma
• Biocad
• Biocon
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celltrion
• Chugai Pharmaceutical
• DARA BioSciences
• EddingPharm
• Eisai
• Galena Biopharma
• Halozyme Therapeutics
• Hospira
• Mylan
• Oncothyreon
• Pfizer
• ProStrakan
• Puma Biotechnology
• Sun Pharmaceutical Industries
• Synta Pharmaceuticals
• Teva Pharmaceutical

Market Driver
• Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report

Market Challenge
• Poor Diagnosis and Screening
• For a full, detailed list, view our report

Market Trend
• Increase in Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size, market worth be of the global HER-2 positive breast cancer market in 2019 and what will the growth rate be?
• What are the key market trends of the global HER-2 positive breast cancer market?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
• Title - HER-2 Positive Breast Cancer Market, market research and industry analysis, market size